FDA Brief

Warning letters Drugs

FDA warning letter to

Global Sanitizers LLC

High riskIssued Nov 8, 2021Posted Nov 16, 2021Division of Pharmaceutical Quality Operations IV

Global Sanitizers' hand sanitizers were adulterated with methanol substitution and had serious CGMP violations.

What happened

FDA inspected Global Sanitizers' Las Vegas drug manufacturing facility from February 23 to March 1, 2021, and collected samples of labeled and unlabeled hand sanitizers. Laboratory testing found a product labeled to contain 70% ethanol contained on average 0% ethanol and 58% methanol, and a market sample labeled 70% ethanol contained 32% ethanol and 7.4% methanol. The letter also cites CGMP failures and misbranding/unapproved new drug issues.

What FDA found

  1. The hand sanitizer labeled to contain ethanol was substituted wholly or partly with methanol, a toxic chemical.

    FD&C Act section 501(d)(2), 21 U.S.C. 351(d)(2)
  2. The quality control unit lacked written procedures and adequate personnel and did not adequately control or test incoming bulk hand sanitizer or review batch records.

    21 CFR 211.22
  3. MEDICALLY MINDED 100% THC FREE Hand Sanitizer Gel was an unapproved new drug because CBD and CBG were not active ingredients in an applicable monograph.

    FD&C Act section 505(a), 21 U.S.C. 355(a)
  4. MEDICALLY MINDED 100% THC FREE Hand Sanitizer Gel was misbranded because it did not meet section 505G marketing requirements and had no approved application.

    FD&C Act section 502(ee), 21 U.S.C. 352(ee)
  5. The MEDICALLY MINDED Hand & Surface Sanitizer Spray Drug Facts panel included extraneous surface-sanitizer information.

    FD&C Act section 502(c), 21 U.S.C. 352(c); 21 CFR 201.66(d)(7)
  6. Two hand sanitizers were packaged in clear, colorless 8-oz bottles that resemble drinking water bottles.

    FD&C Act section 502(i)(1), 21 U.S.C. 352(i)(1)

What FDA wants

FDA asks the company to provide a detailed investigation, supplier and raw-material lists, all U.S. batch lists and reconciliation, complete batch records, an independent material-system review, a quality-unit remediation plan, and a documentation assessment. The provided letter does not state a response deadline.

Who should pay attention

  • consumers who use hand sanitizers
  • retailers and distributors selling MEDICALLY MINDED or American Screening products
  • brands that buy bulk hand sanitizer from contract manufacturers

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. World Perfumes Inc.

    World Perfumes failed to test drug ingredients for toxic contaminants and had inadequate water, FDA says.

    High risk
  2. RNA Bio/Pharma, Incorporated

    FDA found RNA Bio/Pharma failed to test homeopathic oral liquid drugs for dangerous contaminants and did not validate its water system.

    High risk
  3. Kabana Skin Care LLC

    Kabana Skin Care failed to test OTC drug ingredients and finished products, prompting a recall and halt of U.S. drug manufacturing.

    High risk
  4. Ningbo Riway Industrial Co., Ltd.

    Ningbo Riway Industrial, an OTC drug maker in China, was cited for manufacturing-practice failures and unapproved antiseptic wipes.

    High risk